LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling

Emerging evidence suggests that long non-coding RNAs (lncRNA) play critical roles in the development and progression of diverse cancers including hepatocellular carcinoma (HCC), but the underlying molecular mechanisms of lncRNAs that are involved in hepatocarcinogenesis have not been fully explored. Methods: In this study, we profiled lncRNA expression in 127 pairs of HCC and nontumor liver tissues (a Discovery Cohort) using a custom microarray. The expression and clinical significance of lncCSMD1-1 were then validated with qRT-PCR and COX regression analysis in a Validation Cohort (n=260) and two External Validation Cohorts (n=92 and n=124, respectively). In vitro and in vivo assays were performed to explore the biological effects of lncCSMD1-1 on HCC cells. The interaction of lncCSMD1-1 with MYC was identified by RNA pull-down and RNA immunoprecipitation. The role of LncCSMD1-1 in the degradation of MYC protein was also investigated. Results: With microarray, we identified a highly upregulated lncRNA, lncCSMD1-1, which was associated with tumor progression and poor prognosis in the Discovery Cohort, and validated in another 3 HCC cohorts. Consistently, ectopic expression of lncCSMD1-1 notably promotes cell proliferation, migration, invasion, tumor growth and metastasis of HCC cells in in vitro and in vivo experiments. Gene expression profiling on HCC cells and gene sets enrichment analysis indicated that the MYC target gene set was significantly enriched in HCC cells overexpressing lncCSMD1-1, and lncCSMD1-1 was found to directly bind to MYC protein in the nucleus of HCC cells, which resulted in the elevation of MYC protein. Mechanistically, lncCSMD1-1 interacted with MYC protein to block its ubiquitin-proteasome degradation pathway, leading to activation of its downstream target genes. Conclusion: lncCSMD1-1 is upregulated in HCC and promotes progression of HCC by activating the MYC signaling pathway. These results provide the evidence that lncCSMD1-1 may serve as a novel prognostic marker and potential therapeutic target for HCC.

[1]  Li Zhao,et al.  Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis , 2020, Theranostics.

[2]  M. Guan,et al.  Long noncoding RNA PiHL regulates p53 protein stability through GRWD1/RPL11/MDM2 axis in colorectal cancer , 2020, Theranostics.

[3]  Rui Chen,et al.  LncRNA MATN1-AS1 prevents glioblastoma cell from proliferation and invasion via RELA regulation and MAPK signaling pathway. , 2019, Annals of translational medicine.

[4]  Y. Kong,et al.  CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/β-catenin Signaling. , 2019, Current cancer drug targets.

[5]  Y. Liao,et al.  Long noncoding RNA GAS5 induces abdominal aortic aneurysm formation by promoting smooth muscle apoptosis , 2019, Theranostics.

[6]  M. Dai,et al.  Writing and erasing MYC ubiquitination and SUMOylation , 2019, Genes & diseases.

[7]  Hui-Yun Wang,et al.  miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer , 2019, Cell Death & Disease.

[8]  Hongchuan Jin,et al.  Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness , 2019, Cell Death & Disease.

[9]  C. Blanpain,et al.  EMT Transition States during Tumor Progression and Metastasis. , 2019, Trends in cell biology.

[10]  Manjima Chatterjee,et al.  Emerging roles of long non-coding RNAs in cancer , 2019, Journal of Biosciences.

[11]  L. Mao,et al.  LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation , 2019, Cell Death & Disease.

[12]  Zechuan Zhang,et al.  The long non-coding RNA Linc-GALH promotes hepatocellular carcinoma metastasis via epigenetically regulating Gankyrin , 2019, Cell Death & Disease.

[13]  Mengqing Li,et al.  LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway , 2019, Theranostics.

[14]  Liye Ma,et al.  Genome-wide screening identifies oncofetal lncRNA Ptn-dt promoting the proliferation of hepatocellular carcinoma cells by regulating the Ptn receptor , 2019, Oncogene.

[15]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[16]  Michael P. Schroeder,et al.  Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia , 2018, bioRxiv.

[17]  Min Zhang,et al.  lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. , 2018, Cancer cell.

[18]  J. Locasale,et al.  Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells , 2018, Nature Cell Biology.

[19]  M. Wang,et al.  LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge , 2018, Cell Death & Disease.

[20]  J. Gu,et al.  Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development , 2017, Nature Communications.

[21]  M. Kudo,et al.  Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.

[22]  M. Kris,et al.  Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Fernández-Barrena,et al.  Novel lncRNA T-UCR as a potential downstream driver of the Wnt/β-catenin pathway in hepatobiliary carcinogenesis , 2016, Gut.

[24]  Michael C. Smith,et al.  A review in the treatment of oncologic emergencies , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[25]  Tian-Tian Sun,et al.  LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. , 2016, Cancer discovery.

[26]  A. Kriegstein,et al.  A Primate lncRNA Mediates Notch Signaling during Neuronal Development by Sequestering miRNA , 2016, Neuron.

[27]  M. Dinger,et al.  Long noncoding RNAs in cancer: mechanisms of action and technological advancements , 2016, Molecular Cancer.

[28]  Wen Tan,et al.  Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation , 2016, Nature Genetics.

[29]  Shuhan Sun,et al.  Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1 , 2016, Hepatology.

[30]  Liwei Xie,et al.  The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells. , 2015, Gastroenterology.

[31]  Feng Liu,et al.  mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. , 2013, Cell metabolism.

[32]  Xiao Yang,et al.  Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells , 2013, Gut.

[33]  D. Zimonjic,et al.  Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: Potential prospects for combined targeted therapeutics , 2012, International journal of oncology.

[34]  L. Hurley,et al.  Targeting MYC Expression through G-Quadruplexes. , 2010, Genes & cancer.

[35]  S. Thorgeirsson,et al.  Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. , 2009, Cancer research.

[36]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[37]  Robert D Cardiff,et al.  Developmental Context Determines Latency of MYC-Induced Tumorigenesis , 2004, PLoS biology.

[38]  M. Muroni,et al.  Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. , 2003, Carcinogenesis.

[39]  Mei Wang,et al.  Expression of p53 and C-myc genes and its clinical relevance in the hepatocellular carcinomatous and pericarcinomatous tissues. , 2002, World journal of gastroenterology.

[40]  K. Zeller,et al.  Function of the c-Myc oncogenic transcription factor. , 1999, Experimental cell research.

[41]  Y. Morishita,et al.  Amplification of c-myc in Hepatocellular Carcinoma: Correlation with Clinicopathologic Features, Proliferative Activity and p53 Overexpression , 1999, Oncology.

[42]  D. Calvisi,et al.  Correlation of c‐myc overexpression and amplification with progression of preneoplastic liver lesions to malignancy in the poorly susceptible wistar rat strain , 1999, Molecular carcinogenesis.

[43]  L. Gaspa,et al.  c‐myc amplification in pre‐malignant and malignant lesions induced in rat liver by the resistant hepatocyte model , 1996, International journal of cancer.

[44]  M. Eilers,et al.  Ubiquitination of Myc: proteasomal degradation and beyond. , 2008, Ernst Schering Foundation symposium proceedings.